iOS 26 Public Beta Release Date: Exactly When Apple's iPhone Software Will Go Live
Apple announced the next big iPhone software back in June, set to go on general release this fall. It's called iOS 26 and its new design has made it highly anticipated. If you're keen to try iOS 26, it's about to become available in the first public beta – and more information has now come to light. Here's what's happening.
Apple iOS 26 coming soon
Apple announced in June that the release of iOS 26 would first appear as developer betas as usual, with the first public beta set for July. When it reaches general release it will be on the 2025 releases, iPhone 17 series, as well the iPhone 16 sereis and some earlier models.
That's the normal schedule, though the public beta routinely arrives around the middle of the month — so the week beginning Monday, July 14 seemed most likely. That's come and gone, of course, but it looks like this week could be the one we're waiting for.
In the latest Power On newsletter, Bloomberg's Mark Gurman addressed the question. He had already posted on X that the public beta would land around Wednesday, July 23. Now, he has expanded on this reasoning.
'All indications are that iOS 26 should go into the public beta phase this coming week. This typically happens by the middle of July, so the software is a bit later than usual. Given that iOS 26 is such a significant design overhaul, it makes sense that Apple would want to take a little extra time to get things right,' Gurman said.
And there's another reason things seem to be running a little late, which is that instead of using the third developer beta as the basis for the public beta, which is the usual one, 'It seems likely that this public beta will match up with the fourth developer beta version,' this time, Gurman goes on.
This means that although it's a little later, it'll be based on a more stable release, assuming Apple is improving its beta software with each release.
Since this is for public use, better software will be welcome. There have been tweaks to the Liquid Glass design which is the marquee feature in iOS 26, so maybe developer beta 4/public beta 1, will have something closer to the final look.
iOS 26 Public Beta Release Date
This week looks most likely: Apple said July and after this week, there are only three days in July left.
I believe it will be released the day after the fourth developer beta, so if that lands on Monday, July 21, the public beta will be Tuesday, July 22.
Gurman's proposed date of July 23 is also possible, but keep an eye out for dev beta news on Monday. I'll be updating the news, so please check back.
Updating this post on Monday, July 21, I can see there's greater clarity of what's happening. I know, it's unusual to make a prediction based on something that hasn't happened, but there's been no fourth developer beta yet. I don't believe it will come today, which makes me think that Tuesday will see the release of the fourth developer beta, which forms the basis for the first public beta.
It's theoretically possible that the public beta could land on the same day as the latest developer beta, but I don't buy it. Much more likely is that the public beta will follow the next day, Wednesday, 23 July, exactly as Gurman predicted, or just possibly on Thursday, 24 July, depending on whether there are any last-minute hiccups.
Remember, this developer beta cycle began with an unprecedented re-release of the first beta, just days after the initial release.
What About The General Release?
The expectation of a September release remains in place. 'Does that mean the final software will ultimately ship later than expected,' Gurman asks, adding, 'Probably not, since the developer versions remain on track.'
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Forbes
18 minutes ago
- Forbes
Porn Ban—New Threat For Millions Of Smartphone Users
Do not put yourself at risk. Here we go again. Millions of iPhone and Android users are suddenly at risk as the latest porn ban comes into effect. But it turns out the most serious threat to all those smartphone users is not the content, but the dangerous workarounds. In the U.S., as state after state has passed porn ban legislation, users have turned to virtual private networks (VPNs) to maintain their adult content fix. These apps tunnel web traffic via remote servers. And if those servers are located in a different state or country, the porn site thinks the phone is there as well. The porn ban is bypassed. Now the U.K. has enacted its own version of this leaky, pointless legislation, resulting in VPNs suddenly dominating app download charts. One app developer told BBC News, 'it had seen an 1,800% spike in downloads' and many others have experienced the same. Similar surges have been seen in the U.S. as each new ban comes into effect. The reality is that the bans or requirement for age verification — which amount to the same when users don't want to associate real-world identifies with porn sites — do not work. Much worse though, these countermeasures are dangerous and are putting millions at risk. To run a VPN, a developer needs to operate expensive infrastructure — the servers and network capacity to route traffic between devices and websites. Good VPNs offer a menu of locations, enabling users to pick the country or state where they will seem to be. Porn sites take your IP address at face value. If there's a ban or restriction in your location but your IP address suggests you're somewhere else, you will be granted access. It would be very easy for the websites to check if you're using a VPN. A clash between your IP address and your browser fingerprints for example. But they don't. The risk is that users don't need a complex, fully-featured VPN to beat the bans. Any app will do. And China's free app industry is happy to oblige. Using a free VPN without good security and data protection is very much worse than using no app at all. Researchers have even found many free VPNs are linked to the Chinese government and its military. The Tech Transparency Project warns 'millions of Americans have downloaded apps that secretly route their internet traffic through Chinese companies.' Top10VPN's Simon Migliano says this means 'the risks are too great,' and 'in light of these findings, I strongly urge users to avoid Chinese-owned VPNs altogether." You should actually avoid any free VPN. Either use one you subscribe to, or one from a bluechip provider which is an add-on to its other services. As BeyondTrust's James Maude points out, 'if you aren't paying for a product, you are the product; these VPN services are a perfect example of the hidden costs of free apps.' My advice on VPNs is simple:
The Verge
18 minutes ago
- The Verge
India overtakes China in smartphone exports to the US.
Posted Jul 29, 2025 at 6:26 AM UTC Follow topics and authors from this story to see more like this in your personalized homepage feed and to receive email updates. Thomas Ricker Posts from this author will be added to your daily email digest and your homepage feed. See All by Thomas Ricker Posts from this topic will be added to your daily email digest and your homepage feed. See All Apple Posts from this topic will be added to your daily email digest and your homepage feed. See All iPhone Posts from this topic will be added to your daily email digest and your homepage feed. See All News Posts from this topic will be added to your daily email digest and your homepage feed. See All Policy Posts from this topic will be added to your daily email digest and your homepage feed. See All Tech
Yahoo
an hour ago
- Yahoo
ViroCell Biologics and AvenCell Therapeutics Announce Retroviral Vector Manufacturing Collaboration to Accelerate Development of Novel Allogeneic CAR-T Therapies for Blood Cancers
AvenCell selected ViroCell for retroviral vector CDMO services to drive its pipeline of innovative allogeneic CAR T-cell therapies, based on ViroCell's deep expertise and track record. LONDON & NEW YORK, July 29, 2025--(BUSINESS WIRE)--ViroCell Biologics ("ViroCell"), a specialist viral vector Contract Development and Manufacturing Organisation ("CDMO") for cell and gene therapy (CGT) clinical trials, announces a manufacturing collaboration with and the successful delivery of a novel retroviral vector to AvenCell Therapeutics, Inc. ("AvenCell"), a leading clinical-stage cell therapy company focused on advancing allogeneic switchable CAR-T cell therapies. This first retroviral vector will be used to manufacture AVC-203, an investigational CD19/CD20 dual-targeted cell therapy for the treatment of B cell malignancies and autoimmune diseases. AvenCell's AV203 is its second investigational cell therapy using its differentiated allogeneic engineering to provide an "off-the-shelf" product engineered to overcome graft-versus-host disease as well as graft rejection by host T and Natural Killer ("NK") cells. AVC-203 is designed to achieve superior efficacy compared to currently-approved CAR-Ts while enabling immediate treatment and greater patient access at much lower cost and complexity. The further inclusion of AvenCell's RevCAR™ receptor in AVC203 allows for additional antigen targeting (with "off/on" capability in vivo) beyond CD19 and CD20. AvenCell selected ViroCell as its partner to manufacture the retroviral vector for this program based on the CDMO's expertise and track record in delivering high yield vectors at speed. Incorporating a cell line acquired by AvenCell into the GMP manufacturing process, ViroCell successfully delivered a high yield vector while meeting AvenCell's accelerated timeline. This program evidences ViroCell's ability to deliver a bespoke, complex manufacturing process in the allogeneic CAR-T cell therapy space, ultimately, enabling AvenCell's timelines for clinical entry. AvenCell's AVC-203 is expected to enter a first-in-human phase I study in patients with relapsed/refractory B cell lymphoma in H2/2025. John W. Hadden II, CEO of ViroCell, commented: "We are thrilled to partner with AvenCell and support their innovative allogeneic CAR-T therapy platform. I am proud of Team ViroCell's accomplishments on the successful end-to-end delivery of this retroviral vector and accelerating a novel therapy into clinical development in an area of high unmet need. We look forward to continuing our work with AvenCell on their exciting platform." Andrew Schiermeier, Ph.D., CEO, AvenCell, added: "We are delighted with ViroCell's performance in process development and GMP manufacture of this complex retroviral vector. We selected ViroCell to support our platform because we knew that they could execute reliably in areas where other CDMOs can't. The delivery of this retroviral vector for AVC-203 is proof that our trust in ViroCell was well placed." Notes to editor: ViroCell ViroCell Biologics is an innovation-driven Contract Development and Manufacturing Organization ("CDMO") focused exclusively on the design, de-risking, and GMP manufacture of viral vectors for clinical trials. Built around one of the most prolific academic viral vector manufacturing teams, ViroCell was created to address the global demand for precisely engineered viral vectors. The team leverages its deep track record to help clients to de-risk and accelerate novel cell and gene therapies into and through clinical development, with a mission of being the partner of choice for corporate and academic innovators. Focused initially on manufacturing lentiviral and retroviral vectors, ViroCell enables clients to start clinical trials on a scalable platform, delivering value by reducing costs, time and regulatory risk. AvenCell Therapeutics AvenCell derives its name from the French word "avenir" to reflect the aim to be the FUTURE of cell therapy. AvenCell is building a truly transformative cell therapy company that targets difficult-to-treat cancers, with its lead programs focusing on acute myeloid leukemia (AML) and additional programs targeting other hematological malignancies. AvenCell was formed with the goal to create truly allogeneic cells that persist as long or longer than autologous therapies and develop a universal and switchable construct that allows complete control and target redirection of T cells after they are infused into a patient. Integration of these two platforms allows for complete separation of the manufacturing of cells from ultimate patient and cancer target, thus providing significant scalability potential at orders of magnitude more efficient than current approaches. AvenCell Therapeutics, Inc. was launched in 2021 by Blackstone Life Sciences, Cellex Cell Professionals, and Intellia Therapeutics. AvenCell is headquartered in Watertown, Massachusetts with additional R&D and manufacturing operations in Dresden, Germany. View source version on Contacts For more information, please contact: ViroCell John W. Hadden II, CEOinfo@ For media enquiries, please contact: ViroCell – FTI Consulting Simon Conway / Tim StamperViroCell@ +44 (0)20 3727 1000 AvenCell – H Advisors Emma +1 (917) 763-6685 擷取數據時發生錯誤 登入存取你的投資組合 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤
